{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-007956","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2022-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.134369+00:00","generated_at":"2026-06-26T14:46:51.193052+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulmatrix reports 2021 revenue $5.2M, net loss $20.2M; cash $53.8M; pipeline milestones set","bullets":["Revenue $5.2M in 2021 vs $12.6M in 2020; net loss $20.2M vs $19.3M; EPS ($8.63).","Cash $53.8M at Dec 31, 2021; raised $46.75M in 2021; funded into Q1 2024.","Hired Dr. Margaret Wasilewski as CMO; completed 1-for-20 reverse stock split; regained Nasdaq compliance.","Pulmazole Phase 2b in ABPA to start Q1 2023, data mid-2024; PUR3100 Phase 1 in Australia Q3 2022.","PUR1800 Phase 1b met safety endpoint; preclinical tox supports chronic dosing in COPD, asthma, IPF."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-007956","json":"https://secwatch.observer/filing/0001493152-22-007956.json","markdown":"https://secwatch.observer/filing/0001493152-22-007956.md","text":"https://secwatch.observer/filing/0001493152-22-007956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222007956/0001493152-22-007956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222007956/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T14:46:51.193052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}